Prognostic Value of Pulmonary Artery Systolic Pressure in Severe Rheumatic Mitral Stenosis
You-Jung Choi,Jah Yeon Choi,Jieun Lee,Byoung Geol Choi,Soohyung Park,Dong Oh Kang,Eun Jin Park,Ji Bak Kim,Seung-Young Roh,Cheol Ung Choi,Jin Won Kim,Eung Ju Kim,Seung-Woon Rha,Chang Gyu Park,Hwan Seok Yong,Man-Jong Baek,Jin Oh Na
DOI: https://doi.org/10.1161/circimaging.123.016302
2024-10-16
Circulation Cardiovascular Imaging
Abstract:Circulation: Cardiovascular Imaging, Volume 17, Issue 10, Page e016302, October 1, 2024. BACKGROUND:Current guidelines recommend intervention for asymptomatic rheumatic mitral stenosis (MS) with mitral valve area ≤1.5 cm2based on indicators including pulmonary arterial systolic pressure (PASP) >50 mm Hg and new-onset atrial fibrillation; however, evidence supporting this is lacking.METHODS:This single-center retrospective study included patients with rheumatic MS between 2006 and 2022. Pulmonary hypertension was evaluated by using echocardiography to estimate PASP. Primary outcomes were major adverse cardiovascular events (MACE), including all-cause mortality, hospitalization for heart failure, and arterial thromboembolic events for up to 5 years.RESULTS:Overall, 287 patients with severe rheumatic MS were enrolled (mean age, 62.5±11.3 years; 74.6% women). During a median follow-up of 2.52 years, MACE occurred in 99 patients. There were no differences in echocardiographic parameters, such as the mean mitral valve pressure gradient, mitral valve area, and proportion of mitral valve area 50 mm Hg than in those with ePASP ≤50 mm Hg (log-rankP<0.001); however, atrial fibrillation was not a significant prognostic indicator. As a continuous variable, ePASP (mm Hg) was a significant predictor of MACE (adjusted hazard ratio, 1.027 [95% CI, 1.011–1.042];P 45 mm Hg, which was an independent predictor of MACE in patients with severe rheumatic MS (adjusted hazard ratio, 2.127 [95% CI, 1.424–3.177];P 45 mm Hg) as a predictor of an unfavorable prognosis.
radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems